Insider trade

CEO exercised or converted 7,040 BIIB derivative securities

Traded Dec 1, 2025 · Filed Dec 3, 2025

BiogenBIIB

7,040
Shares

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 1, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 3, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000875045-25-000052
Filed / recorded

Dec 3, 2025, 9:42 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

BIOGEN INC.

Issuer CIK

875045

Ticker

BIIB

Reporting person

Christopher Viehbacher

Relationship

Director, Officer

Officer title

President and CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Dec 1, 2025

Transaction code

M

Shares / units

7,040

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

19,847

Ownership form

Direct

Amendment

No

Around the same time

10mo ago

3,404Shares · @ $177.78

Routine share withholding; mechanical by default.

Why it stands out Official record

10mo ago

7,040Derivative units

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

11mo ago

695Shares

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record